Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM-MSCs in Severe COVID-19
NCT04346368Phase 2Unknown
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesenchymal stem cells in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoints: Changes of oxygenation index (PaO2/FiO2) at Month 6 and Side effects in the BM-MSCs treatment group. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04346368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346368.